BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campbell JM, Bateman E, Peters MD, Bowen JM, Keefe DM, Stephenson MD. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics 2016;17:435-51. [DOI: 10.2217/pgs.15.180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Palmirotta R, Carella C, Silvestris E, Cives M, Stucci SL, Tucci M, Lovero D, Silvestris F. SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget 2018;9:25355-82. [PMID: 29861877 DOI: 10.18632/oncotarget.25256] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
2 Campbell JM. What's the evidence for this evidence? JBI Database System Rev Implement Rep 2016;14:1-2. [PMID: 27635738 DOI: 10.11124/JBISRIR-2016-003062] [Reference Citation Analysis]
3 Wardill HR, Tissing WJE. Determining risk of severe gastrointestinal toxicity based on pretreatment gut microbial community in patients receiving cancer treatment: a new predictive strategy in the quest for personalized cancer medicine. Curr Opin Support Palliat Care 2017;11:125-32. [PMID: 28333867 DOI: 10.1097/SPC.0000000000000265] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
4 Campbell JM, Bateman E, Stephenson MD, Bowen JM, Keefe DM, Peters MDJ. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother Pharmacol 2016;78:27-39. [DOI: 10.1007/s00280-016-3043-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
5 Cecchin E, De Mattia E, Ecca F, Toffoli G. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Drug Resist Updat. 2018;39:18-40. [PMID: 30075835 DOI: 10.1016/j.drup.2018.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
6 Sissung TM, Cordes L, Peer CJ, Gandhy S, Redman J, Strauss J, Figg WD. Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD. Pharmacogenomics 2021;22:81-5. [PMID: 33305610 DOI: 10.2217/pgs-2020-0120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hong X, Lin J, Gu W. Risk factors and therapies in vascular diseases: An umbrella review of updated systematic reviews and meta‐analyses. J Cell Physiol 2019;234:8221-32. [DOI: 10.1002/jcp.27633] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, Buonadonna A, Solfrini V, Innocenti F, Toffoli G. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. Clin Pharmacol Ther 2017;102:123-30. [PMID: 28074472 DOI: 10.1002/cpt.615] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
9 Goričar K, Dolžan V, Lenassi M. Extracellular Vesicles: A Novel Tool Facilitating Personalized Medicine and Pharmacogenomics in Oncology. Front Pharmacol 2021;12:671298. [PMID: 33995103 DOI: 10.3389/fphar.2021.671298] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, Polesel J, D'Andrea M, Pella N, Buonadonna A, Favaretto A, Toffoli G. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. Int J Mol Sci 2017;18:E1366. [PMID: 28653974 DOI: 10.3390/ijms18071366] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
11 Wardill HR, Sonis ST, Blijlevens NMA, Van Sebille YZA, Ciorba MA, Loeffen EAH, Cheng KKF, Bossi P, Porcello L, Castillo DA, Elad S, Bowen JM; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer 2020;28:5059-73. [PMID: 32592033 DOI: 10.1007/s00520-020-05579-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Al-Mahayri ZN, Patrinos GP, Ali BR. Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy. Front Pharmacol 2020;11:445. [PMID: 32351390 DOI: 10.3389/fphar.2020.00445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zanger UM, Klein K, Kugler N, Petrikat T, Ryu CS. Epigenetics and MicroRNAs in Pharmacogenetics. Pharmacogenetics. Elsevier; 2018. pp. 33-64. [DOI: 10.1016/bs.apha.2018.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Braccini S, Rizzi G, Biancalana L, Pratesi A, Zacchini S, Pampaloni G, Chiellini F, Marchetti F. Anticancer Diiron Vinyliminium Complexes: A Structure-Activity Relationship Study. Pharmaceutics 2021;13:1158. [PMID: 34452119 DOI: 10.3390/pharmaceutics13081158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Campbell JM, Stephenson MD, Bateman E, Peters MDJ, Keefe DM, Bowen JM. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics J 2017;17:21-8. [DOI: 10.1038/tpj.2016.58] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]